RecruitingPhase 2NCT07013201
Rare condition
Pustulosis palmaris et plantaris
6
studies recruiting now
as of 7 Sept 2026
34
studies registered in total
as of 7 Sept 2026
13
countries with a recruiting site
as of 7 Sept 2026
27 Apr 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 3NCT07219420
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
RecruitingNot applicableNCT07552454
Picankibart in Palmoplantar Pustulosis
RecruitingPhase 4NCT07503652
Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar Pustulosis
RecruitingNCT05994976
Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 6 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Pustulosis palmaris et plantaris study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Pustulosis palmaris et plantaris
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the genes involved (IL36RN, AP1S3).
Treatments being studied
46 approved treatments and 137 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Infliximab (Flixabi)Approved: Deucravacitinib (Sotyktu)Approved: Isopropyl Alcohol (Isopropyl alcohol component of chloraprep)Approved: Roflumilast (Daliresp)Approved: Coal Tar (Alphosyl)Approved: Spesolimab (Spevigo)Approved: Desoximetasone (Desoximetasone)Approved: Tacalcitol (Curatoderm)Approved: Prednisone (Cortan)Approved: Adalimumab (Amgevita)Approved: Dexamethasone (Aeroseb-dex)Approved: Calcipotriene (Calcipotriene)Approved: Ixekizumab (Taltz)Approved: Etretinate (Tegison)Approved: Calcitriol (Calcijex)Approved: Menthol (Aqua-cool)Approved: Fluocinolone Acetonide (Capex)Approved: Tildrakizumab (Ilumetri)Approved: Bimekizumab (Bimzelx)Approved: Methotrexate (Ebetrex)Approved: Efalizumab (Raptiva)Approved: Clobetasol Propionate (Clarelux)Approved: Dexamethasone Sodium Phosphate (Ak-dex)Approved: Hydrocortisone (Acetasol hc)Approved: Betamethasone Dipropionate (Alphatrex)Approved: BergaptenApproved: Apremilast (Apremilast accord)Approved: Brodalumab (Kyntheum)Approved: Methotrexate Sodium (Abitrexate)Approved: Fumaric AcidApproved: Anthralin (Alphodith)Approved: Secukinumab (Cosentyx)Approved: Zinc Oxide (Anusol)Approved: Methoxsalen (8-mop)Approved: Tapinarof (Vtama)Approved: Cyclosporine (Capimune)Approved: Acitretin (Acitretin)Approved: Salicylic Acid (Acnisal)Approved: Etanercept (Benepali)Approved: Ustekinumab (Stelara)Approved: Tazarotene (Arazlo)Approved: Guselkumab (Tremfya)Approved: Prednisolone (Cortalone)Approved: Trioxsalen (Trisoralen)Approved: Dimethyl Fumarate (Dimethyl fumarate accord)Approved: Risankizumab (Skyrizi)
Phase 3Piclidenoson
Phase 3Halobetasol Propionate (Bryhali)
Phase 3Tacrolimus Anhydrous
Phase 3Certolizumab Pegol (Cimzia)
Phase 3Voclosporin (Lupkynis)
Phase 3Cyanocobalamin (Behepan)
Phase 3Pefcalcitol
Phase 3Tofacitinib
+ 129 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).